Axovant Sciences Ltd. (Nasdaq: AXON) reported disappointing results from a Phase 2b HEADWAY and a pilot Phase 2 Gait and Balance study of intepirdine. Shares of the biopharmaceutical plummeted $3.06 to close at $2.31.
Disappointing study results for Axovant Sciences
January 08, 2018 at 18:21 PM EST